Trials

由生物医学中心出版。ISSN: 1745 - 6215。《临床试验》是一本开放获取、同行评议的在线期刊，涵盖随机对照试验的所有方面的表现和结果。试验将试验并改进创新的方法，以改进关于试验的交流。我们渴望超越发布传统的试验结果文章(尽管这些将包括在内)。我们认为这是一个令人兴奋的机会，可以促进科学和试验报告。在2006年之前，这些试验被发表为当前心血管医学的对照试验(CCTCVM)。所有已发表的CCTCVM文章均可通过试验网站获得，并将继续支持CCTCVM文章网址的引用。所示的影响因素与CCTCVM在2003-4年间发表的文章有关。让所有的内容都开放获取，而不保留版权，审判提供了一种方法，使数据既免费提供，又高度可见的世界各地的审判人员;这将有利于你的出版物在同行和社会中的影响。该期刊拥有不受限制的空间，并利用了电子出版的所有技术可能性。到目前为止，期刊主要报道试验的结果，很少报道为什么以及如何进行试验。试验的报告已经限制由作者和编辑,双方往往只选择结果测量的一个子集,而后者经常词限制文章很难沟通进行审判的教训,更不用说包含足够的细节的审判。互联网提供了无限的空间和交互性，我们热衷于利用这些特性。例如，测试者将能够提供真实科学记录所需的细节，并做更多的工作使文章的信息能够被各种读者群体理解。他们还将不仅能够交流所有的结果测量，以及不同的分析和解释，而且能够深入地描述他们做了什么和学到了什么。这种直接经验的分享对提高全世界试验的质量和开展工作至关重要。

Published by BioMed Central. ISSN: 1745-6215.Trials is an open access, peer-reviewed, online journal that will encompass all aspects of the performance and findings of randomized controlled trials. Trials will experiment with, and then refine, innovative approaches to improving communication about trials. We are keen to move beyond publishing traditional trial results articles (although these will be included). We believe this represents an exciting opportunity to advance the science and reporting of trials. Prior to 2006, Trials was published as Current Controlled Trials in Cardiovascular Medicine (CCTCVM). All published CCTCVM articles are available via the Trials website and citations to CCTCVM article URLs will continue to be supported. The impact factor shown relates to articles published in CCTCVM during 2003-4. Making all its content open access and not retaining copyright, Trials offers a way to make data both freely available and highly visible to trialists worldwide; this will benefit the impact of your publication among peers and society. The journal has unrestricted space and takes advantage of all the technical possibilities available for electronic publishing. To date, journals have focused on reporting the results of trials, with very little coverage of why and how they are conducted. Reports of trials have been restricted both by authors and editors - both parties often select only a subset of the outcomes measured, while the latter often impose word limits on the articles published making it difficult to communicate the lessons learnt from conducting the trial, let alone include adequate details of how the trial was conducted. The Internet offers both unlimited space and interactivity, and we are keen to harness these attributes. For instance, trialists will be able to provide the detail required to be a true scientific record and do more to make the article's message comprehensible to a variety of reader groups. They will also be able to communicate not only all outcome measures, as well as varying analyses and interpretations, but also in-depth descriptions of what they did and what they learnt. This sharing of direct experience is fundamental to improving the quality and conduct of trials worldwide.